# ClinicalTrials.gov record NCT03634137

> PeptideScanner retained ClinicalTrials.gov record NCT03634137 at 2026-07-30T21:10:03.005Z. Its registry update date was 2018-08-16, and PeptideScanner's reviewed identity mapping was afamelanotide.

- Evidence object: `story:clinicaltrials-gov-nct03634137-afamelanotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-08-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03634137-afamelanotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03634137-afamelanotide-v1.json
- Content SHA-256: `7c9df95383f6599e0e07e97b5a8d34039966931da5f9a38a2f0fd4ecdb25e759`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT03634137 ([`ctg-observation-nct03634137-2018-08-16-357df7d2cf4a`](#source-ctg-observation-nct03634137-2018-08-16-357df7d2cf4a))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03634137 at 2026-07-30T21:10:03.005Z. Its registry update date was 2018-08-16, and PeptideScanner's reviewed identity mapping was afamelanotide. ([`ctg-observation-nct03634137-2018-08-16-357df7d2cf4a`](#source-ctg-observation-nct03634137-2018-08-16-357df7d2cf4a))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03634137 at 2026-07-30T21:10:03.005Z. Its registry update date was 2018-08-16, and PeptideScanner's reviewed identity mapping was afamelanotide. ([`ctg-observation-nct03634137-2018-08-16-357df7d2cf4a`](#source-ctg-observation-nct03634137-2018-08-16-357df7d2cf4a))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03634137-2018-08-16-357df7d2cf4a`](#source-ctg-observation-nct03634137-2018-08-16-357df7d2cf4a))

## Sources

<a id="source-ctg-observation-nct03634137-2018-08-16-357df7d2cf4a"></a>
- **ClinicalTrials.gov record NCT03634137 · retained source version 2018-08-16:357df7d2cf4aa537d2b62086f772a41d3b6c3fdf950a510226bb033dac25e59d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03634137) (`ctg-observation-nct03634137-2018-08-16-357df7d2cf4a`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03634137." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct03634137-afamelanotide-v1.json SHA-256: 7c9df95383f6599e0e07e97b5a8d34039966931da5f9a38a2f0fd4ecdb25e759.